In a trial of metastatic triple-negative breast cancer, AZD5363 significantly extended patients’ overall survival from 12.6 to 19.1 months, vs. placebo, when given with chemotherapy.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,